Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Alliance Grants

Simon Fraser University

$25,000.00

Use of novel bioengineering technology to yield matured cardiomyocytes derived from hiPSCs

FY 2023-24

Summary
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality globally and account for 17.9 million deaths each year. Many studies have shown that the survival rate among patients with CVDs, such as hypertrophic cardiomyopathy (HCM), has improved significantly with newer medical interventions. While medical treatment for heart disease has improved dramatically, many more patients are surviving heart attacks. As a consequence, the incidence of heart failure is reaching epidemic proportions.Animal models of heart disease have proven to be challenging in one's ability to translate those experimental results to the human condition. Thus, the ability to use human induced pluripotent stem cells (hiPSCs) and convert them into beating heart cells (hiPSC-CMs) is an exciting avenue to pursue. However, making the hiPSC-CMs mature enough to behave like adult human heart tissue remains an obstacle. This proposal will invoke an array of novel biomedical engineering technologies to increase the purity and the quantity of hiPSC-CMs. Generating tens of millions of hiPSC-CMs will allow us to use 3D bioprinting cardiac tissue that harbors genetic variants which are thought to underlie very serious CVDs. This approach will significantly improve therapeutic interventions and save lives.
Program
Alliance Grants
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
584658-2023
Name nom
Tibbits, Glen GF
Department département
Biomedical Physiology and Kinesiology
Organization id
5
Institution établissement
Simon Fraser University
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2023
Award amount
25000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Biomedical technology
Research subject en
Génie biomédical
Research subject fr
Technologie biomédicale
Application title
Use of novel bioengineering technology to yield matured cardiomyocytes derived from hiPSCs
Keyword
cardiac arrhythmias; hiPSC-CM maturation; hiPSC-derived cardiomyocytes; hiPSC differentiation; materials science; mechanosensing
Application summary
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality globally and account for 17.9 million deaths each year. Many studies have shown that the survival rate among patients with CVDs, such as hypertrophic cardiomyopathy (HCM), has improved significantly with newer medical interventions. While medical treatment for heart disease has improved dramatically, many more patients are surviving heart attacks. As a consequence, the incidence of heart failure is reaching epidemic proportions.Animal models of heart disease have proven to be challenging in one's ability to translate those experimental results to the human condition. Thus, the ability to use human induced pluripotent stem cells (hiPSCs) and convert them into beating heart cells (hiPSC-CMs) is an exciting avenue to pursue. However, making the hiPSC-CMs mature enough to behave like adult human heart tissue remains an obstacle. This proposal will invoke an array of novel biomedical engineering technologies to increase the purity and the quantity of hiPSC-CMs. Generating tens of millions of hiPSC-CMs will allow us to use 3D bioprinting cardiac tissue that harbors genetic variants which are thought to underlie very serious CVDs. This approach will significantly improve therapeutic interventions and save lives.